Friday, August 05, 2016 10:12:15 AM
BMY IO Combo's:
Couldn't the case be made that BMY would be more likely to do IO combo deals that could be synergistic?
NKTR said they will be combining with a Checkpoint inhibitor later this year in their Phase 1/2 214 study but didn't say which one(s). Their preclinical data shows very good synergy.
I am long NKTR so I am likely very biased
EDIT: Here is a link to NKTR's 214 page with access to their posters
http://www.nektar.com/product_pipeline/oncology_nktr-214.html
Couldn't the case be made that BMY would be more likely to do IO combo deals that could be synergistic?
NKTR said they will be combining with a Checkpoint inhibitor later this year in their Phase 1/2 214 study but didn't say which one(s). Their preclinical data shows very good synergy.
I am long NKTR so I am likely very biased
EDIT: Here is a link to NKTR's 214 page with access to their posters
http://www.nektar.com/product_pipeline/oncology_nktr-214.html
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
